Radiology and Oncology最新文献

{"title":"Is there a correlation between signal intensity ratio of 3T MRI and molecular subtypes of breast cancer?","authors":"Yuanping Tao, Hongyan Chao, Yue Ren, Wanjun Zheng, Yuyou Chen, Liang Du, Huanguo Li, Feng Cui","doi":"10.2478/raon-2026-0029","DOIUrl":"10.2478/raon-2026-0029","url":null,"abstract":"<p><strong>Background: </strong>The study aimed to test whether tumoral signal intensity ratio (SIR) and other indicators of 3T MRI provides information related to molecular subtypes of breast cancer.</p><p><strong>Patients and methods: </strong>Between January 2022 and August 2025, 256 patients with breast cancer underwent 3T MRI. MRI morphological features and quantitative parameters (T1 SIR, T2 SIR, mean apparent diffusion coefficient [ADC] from diffusion-weighted imaging [DWI] and tumor diameter) were compared and measured according to molecular subtypes. Logistic regression was performed to find the related MRI parameters and establish combined parameters. A receiver operating characteristic (ROC) analysis was finally performed to test the diagnostic power of multivariate logistic regression model.</p><p><strong>Results: </strong>263 lesions were considered. Triple-negative (TN) subtype exhibited the highest T2 SIR and lowest T1 SIR (p < 0.05). Mean ADC values in TN were the lowest and highest in human epidermal growth factor receptor 2 (HER2)-enriched type (p < 0.001). Tumor diameter of HER2-enriched was the smallest, and that of triple-negative subtype was the largest (p < 0.001). Independent influencing factors were higher T2 SIR (p = 0.017) and larger tumor diameter (p = 0.011) associated with triple-negative subtype, and T1 SIR (p = < 0.01) was the only quantitative parameter associated with HER2-enriched subtype. The combined parameter (mean ADC + tumor diameter) achieved a largest area under the ROC curve (AUC = 0.781) for separating luminal A subtype.</p><p><strong>Conclusions: </strong>Quantitative MRI parameters are correlated with the molecular subtypes of breast cancer. Combined parameters incorporating T1 SIR and T2 SIR exhibit potential diagnostic utility for differentiating HER2-enriched and triple-negative subtypes, respectively. T1 SIR and T2 SIR can enrich quantitative descriptors from breast MRI.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"367-377"},"PeriodicalIF":2.3,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13548682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148382718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic variability of immune checkpoints in asbestos-related diseases.","authors":"Irma Zeljkovic, Katja Goricar, Tanja Blagus, Alenka Franko, Viljem Kovac, Vita Dolzan","doi":"10.2478/raon-2026-0035","DOIUrl":"10.2478/raon-2026-0035","url":null,"abstract":"<p><strong>Background: </strong>Asbestos exposure is associated with asbestos-related diseases such as pleural plaques, asbestosis, lung cancer, malignant mesothelioma (MM), as well as several other types of cancer. Although the exact mechanism underlying the development of asbestos-related diseases is not yet fully understood, the immune system may play an important role. Immune checkpoints such as programmed cell death receptor 1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) regulate immune responses and are crucial for maintaining immune tolerance, while defects in these mechanisms can lead to the development of cancer. The aim of present study was to investigate the association of polymorphisms in the immune checkpoint genes for PD-1 (<i>PDCD1</i>), PD-L1 (<i>CD274</i>), and CTLA-4 (<i>CTLA4</i>) with the risk of asbestos-related diseases.</p><p><strong>Subjects and methods: </strong>We conducted a retrospective case-control study. The cases included individuals with asbestosis or pleural plaques and MM patients. The controls were asbestos-exposed subjects who did not develop asbestos-related diseases. All subjects were genotyped for <i>PDCD1</i> (rs2227982, rs222798, rs10204525), <i>CD274</i> (rs2297136, rs4143815, rs4742098) and <i>CTLA4</i> (rs5742909, rs4553808, rs231775) polymorphisms using competitive allele-specific PCR. Statistical analysis was performed using logistic regression.</p><p><strong>Results: </strong>Our study showed that the <i>CTLA4</i> rs4553808 polymorphism was associated with a decreased risk of asbestosrelated diseases (OR = 0.34, 95% CI = 0.15-0.74, P = 0.007). Homozygous carriers of polymorphic rs4553808 G allele had a lower risk of developing pleural plaques as well as MM compared to the control group (OR = 0.28, 95% CI = 0.11-0.68, P = 0.01, and OR = 0.38, 95% CI = 0.16 -0.93, P = 0.03, respectively). However, carriers of polymorphic <i>CTLA4</i> rs231775 GG genotype had a higher risk of developing MM compared to the group of subjects with pleural plaques (OR = 1.79, 95% CI = 1.10-2.89, P = 0.02). The other investigated polymorphisms were not associated with any of the asbestos-related diseases.</p><p><strong>Conclusions: </strong><i>CTLA4</i> polymorphisms may play a role in the susceptibility for asbestos-related diseases. Our results may contribute to a better understanding of the pathogenesis and progression of asbestos-related diseases.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"60 2","pages":"271-281"},"PeriodicalIF":2.3,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13307012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148339797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electroporation as a strategy to improve the efficacy of chemotherapy in neuroblastoma: an in vitro study.","authors":"Jonathan J Neville, Laura Privitera, Jingchen Sun, Renata Da Costa Magueta, Piotr Golda, Adam C Sedgwick, Paolo De Coppi, Ismael Diez Perez, Premal A Patel, John Anderson, Stefano Giuliani","doi":"10.2478/raon-2026-0028","DOIUrl":"10.2478/raon-2026-0028","url":null,"abstract":"<p><strong>Background: </strong>Reversible electroporation involves the use of pulsed electric fields to temporarily disrupt and permeabilise cell membranes. Electroporation combined with chemotherapy - electrochemotherapy (ECT) - increases tumour cell permeability to chemotherapeutic drugs and enhances their effect. We investigated the efficacy of electroporation and cisplatin as a treatment for neuroblastoma <i>in vitro</i>, and explored whether inhibition of DNA repair mechanisms with olaparib potentiates its effects.</p><p><strong>Materials and methods: </strong>Three immortalised neuroblastoma cell lines were exposed to eight 1 ms square wave pulses of 0-0.93 kV/cm electric fields in the presence of propidium iodide and reversible electroporation was identified by detecting live propidium iodide positive cells by flow cytometry. Intracellular cisplatin and olaparib levels after electroporation were investigated by measuring intracellular platinum via inductively coupled plasma mass spectrometry and by quantifying a fluorescent olaparib with flow cytometry. Cells were exposed to electroporation in the presence of cisplatin and olaparib, and cell death was quantified by flow cytometry. Presence of DNA damage was evaluated by quantifying γ-H2AX immunofluorescence.</p><p><strong>Results: </strong>Reversible electroporation (0.74 kV/cm) increased intracellular cisplatin and olaparib levels. Electroporation with cisplatin (1-100 μM) significantly reduced cell viability compared to cisplatin treatment in all cell lines. The addition of olaparib (5 μM) modestly potentiated the effects of cisplatin and electroporation. DNA damage was significantly higher following treatment with a combination of electroporation, cisplatin and olaparib, compared to each treatment alone.</p><p><strong>Conclusions: </strong>Electroporation with cisplatin appears effective against neuroblastoma <i>in vitro</i>. Further work will investigate the efficacy of electroporation with cisplatin using clinical ECT devices.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"60 2","pages":"244-252"},"PeriodicalIF":2.3,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13307008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148339835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vactosertib enhances radiotherapy efficacy by modulating radiation-induced tumor microenvironment remodeling in breast cancer.","authors":"Jiyoung Park, Jiwon Choi, Yhun Yhong Sheen","doi":"10.2478/raon-2026-0034","DOIUrl":"10.2478/raon-2026-0034","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy (RT) is a standard treatment for breast cancer; however, it can induce unfavorable alterations in the tumor microenvironment (TME), including inflammatory responses, fibrosis, and immune dysregulation, which may compromise therapeutic efficacy and contribute to suboptimal treatment outcomes. This study aimed to investigate whether Vactosertib, a TGF-β receptor I inhibitor, could modulate RT-induced TME changes and improve treatment outcomes.</p><p><strong>Materials and methods: </strong>A breast tumor-bearing mouse model was established and treated with RT alone or in combination with Vactosertib. Mice received fractionated irradiation (4 Gy/day for 3 days) and oral administration of Vactosertib (2.5 mg/kg for 2 weeks). Tumor progression, gene expression, cytokine profiles, immune cell infiltration, and fibrosis were analyzed using microarray analysis, quantitative RT-PCR, ELISA, and histological assessments.</p><p><strong>Results: </strong>RT alone reduced tumor volume but induced transcriptional and cytokine changes associated with inflammation and fibrosis within tumor tissues. In contrast, combination treatment with Vactosertib significantly enhanced tumor suppression compared with RT alone. This was accompanied by reduced expression of pro-inflammatory cytokines, decreased collagen deposition, and increased infiltration of CD8+ T cells, indicating a shift toward a more favorable anti-tumor immune microenvironment.</p><p><strong>Conclusions: </strong>These findings suggest that Vactosertib may enhance the therapeutic efficacy of RT by modulating radiation-induced inflammatory and fibrotic changes in the TME, supporting its potential as a rational combination strategy to improve RT outcomes in breast cancer.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"60 2","pages":"262-270"},"PeriodicalIF":2.3,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13307005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148339893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor ablation: emerging uses, challenges, and strategic implementation. A green paper by the Network of Expertise in Cancer (JANE-2), High Tech Medical Resources, network on Physical Methods of Tumor Ablation.","authors":"Julie Gehl, Philippe L Pereira, Colin P Cantwell, Frédéric Deschamps, Anja Kocijancic, Nina Schmidt, Rok Dezman, Greta Chlebopasevienė, Andrei Roman, Maja Cemazar, Gregor Sersa","doi":"10.2478/raon-2026-0030","DOIUrl":"10.2478/raon-2026-0030","url":null,"abstract":"<p><p>The field of oncology has witnessed remarkable progress with the integration of high-tech innovations in tumor ablation. Tumor ablation therapies, such as radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation (Cryo), irreversible electroporation (IRE), and electrochemotherapy (ECT) have evolved beyond conventional boundaries, offering patients less invasive, highly targeted therapeutic options. Since it works across cancer histologies, tumor ablation is being integrated into cancer care at several levels. Tumor ablation is even considered curative in selected patients with small primary or secondary tumors, e.g. in the liver. Furthermore, it is central in treatment of oligometastatic disease or oligoprogression. Finally, ablation is widely used for symptomatic relief when tumors lead to symptoms affecting quality of life. Knowledge about ablative therapies and their inclusion at multidisciplinary team decision making enables effective and more personalized treatment for patients. This review synthesizes emerging applications of these therapies, focusing on artificial intelligence-driven personalization, robotic-assisted precision, and hybrid models combining ablation with systemic treatments, immunotherapy or targeted drug delivery. It also discusses the infrastructural, educational, regulatory, and ethical challenges that influence the clinical adoption of such treatments. Finally, the review presents strategic recommendations for integrating advanced ablation therapies into healthcare systems while ensuring equity, patient trust, and global accessibility.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"60 2","pages":"153-165"},"PeriodicalIF":2.3,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13307015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148339839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weekly measurement of HMGB1 during neoadjuvant chemoradiotherapy in rectal cancer patients: correlations with MRI response and ctDNA.","authors":"Franziska Eckert, Vlatko Potkrajcic, Stephan Clasen, Elgin Hoffmann, Julian Taugner, Olga Seibel-Kelemen, Christopher Schroeder, Maximilian Niyazi, Kerstin Clasen","doi":"10.2478/raon-2026-0033","DOIUrl":"10.2478/raon-2026-0033","url":null,"abstract":"<p><strong>Background: </strong>Biomarkers are desirable to characterize individual tumors and to personalize multimodal treatment in locally advanced rectal cancer patients. In this regard, monitoring of High Mobility Group Box 1 (HMGB1) protein in blood samples is of interest in radiotherapy as HMGB1 is a consensus marker for immunogenic cell death (ICD) during anticancer treatment.</p><p><strong>Patients and methods: </strong>Plasma levels of HMGB1 were monitored weekly during long-term neoadjuvant chemoradiotherapy in 19 patients with locally advanced rectal cancer. HMGB1 levels were correlated with outcome and tumor volumes in magnetic resonance imaging (MRI) pre-therapeutically as well as in week 2 and week 5 of treatment. Furthermore, the association with circulating cell-free tumor DNA (ctDNA) was evaluated.</p><p><strong>Results: </strong>Higher pre-therapeutic levels of HMGB1 correlated positively with bigger initial MRI volumes and higher allele frequencies of ctDNA in the corresponding baseline blood sample. Courses of HMGB1 during treatment were variable and mostly undulating. Predominant ascent was observed in four patients who showed poor pathologic response. Declining levels in week 2 / 3 were associated with bigger percentage decrease of MRI tumor volume at the end of week 2.</p><p><strong>Conclusions: </strong>HMGB1 seems to be associated mostly with tumor burden as indicated by correlation with MRI volumes and ctDNA levels, rather than ICD induction or side effects as previously reported. Changes during treatment might predict clinical disease course.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"60 2","pages":"294-300"},"PeriodicalIF":2.3,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13307003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148339859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of Ki-67 expression in hepatocellular carcinoma: a dual-center study based on T2-weighted imaging habitat analysis.","authors":"Xiaojun Zheng, Lihong Huang, Mengjie Huang, Bin Yu, Shiji Qin, Deyou Huang","doi":"10.2478/raon-2026-0032","DOIUrl":"10.2478/raon-2026-0032","url":null,"abstract":"<p><strong>Background: </strong>Limited research has applied habitat imaging to evaluate the association between T2-weighted magnetic resonance imaging (T2WI-MRI) features and Ki-67 expression in hepatocellular carcinoma HCC). This study aimed to link T2WI habitat-derived parameters to Ki-67 status and aggressiveness in HCC.</p><p><strong>Patients and methods: </strong>This dual-center retrospective study, enrolled patients with pathologically confirmed HCC undergoing preoperative MRI (2020-2024). Using Ki-67 index cutoff (20%). Tumor habitat partitioning was performed using k-means clustering (k = 5), followed by extraction of both habitat-specific radiomic features and conventional whole-tumor features. Feature selection was conducted using least absolute shrinkage and selection operator (LASSO) regression with 10-fold cross-validation. Three predictive models were constructed with the ExtraTrees algorithm: a habitat model, a radiomics model, and a clinical model. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), DeLong test, and decision curve analysis (DCA).</p><p><strong>Results: </strong>T2WI-based habitat imaging enables a noninvasive assessment of intratumoral heterogeneity, significantly improving the prediction of Ki-67 expression status in HCC. This approach may provide a promising imaging biomarker for molecular subtyping and support personalized preoperative treatment strategies.</p><p><strong>Conclusions: </strong>T2WI habitat imaging enables improved Ki-67 prediction, supporting informed therapeutic decisions in HCC.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"60 2","pages":"217-226"},"PeriodicalIF":2.3,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13307014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148339805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced magnetic resonance imaging techniques for structural and functional assessment of salivary glands.","authors":"Jernej Vidmar, Andrej Vovk","doi":"10.2478/raon-2026-0025","DOIUrl":"10.2478/raon-2026-0025","url":null,"abstract":"<p><strong>Background: </strong>Diagnostic paradigms for salivary gland disorders have undergone a radical transformation, shifting from purely morphological descriptions toward multi-parametric tissue characterization. This review evaluates the clinical efficacy of advanced magnetic resonance imaging (MRI) techniques, specifically quantitative T2 mapping and arterial spin labelling (ASL), in order to provide objective biomarkers for glandular pathophysiology. The use of pseudocontinuous ASL (pCASL) for non-invasive perfusion assessment and multi-dynamic multi-echo (MDME) sequences for quantitative mapping was highlighted in a methodical synthesis of recent research. Quantitative T2 mapping demonstrates high diagnostic accuracy in identifying glandular dysfunction; patients with hyposalivation exhibit significantly elevated T2 relaxation times (mean 91.85 ± 8.24 ms) compared to healthy controls (mean 80.69 ± 6.42 ms, p < 0.0001). ASL imaging reveals that parotid glands in Sjögren's syndrome are hyperemic at rest (59.2 ± 22.8 mL/min/100g) but shows dysfunctional microvascular regulation after stimulation. Furthermore, apparent diffusion coefficient (ADC) values effectively differentiate pleomorphic adenomas (> 1.4 × 10-3 mm²/s) from malignant lesions.</p><p><strong>Conclusions: </strong>Advanced MRI provides robust, non-invasive metrics for monitoring radiation-induced damage and assessing the restorative impact of hyperbaric oxygen therapy (HBOT). By facilitating the shift to precision radiology in head and neck medicine, these technologies greatly improve patient quality of life and therapeutic planning.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"166-175"},"PeriodicalIF":2.3,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13307007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT-based 3D-printed coronary artery phantom for imaging projection education.","authors":"Laura Jursa, Masa Kramer, Anja Boc, Nejc Mekis","doi":"10.2478/raon-2026-0027","DOIUrl":"10.2478/raon-2026-0027","url":null,"abstract":"<p><strong>Background: </strong>Coronary artery disease is among the leading causes of death worldwide. The method of choice for coronary artery imaging is catheterization using real-time fluoroscopic images of coronary anatomy and pathology. The aim of the study was to create an anatomically accurate cardiac and coronary artery phantom suitable for learning and practicing image projections in invasive coronary angiography by using computed tomography (CT) image segmentation and 3D printing.</p><p><strong>Materials and methods: </strong>The development of an anatomically accurate heart phantom was carried out in several phases. In the first phase, the material for 3D printing was analysed and the best material with a similar attenuation coefficient to the heart muscle was selected. Then the segmentation of the heart was performed with the 3D Slicer software based on the CT scan. Afterward the phantom of the heart was developed. The anatomy professor of the medical faculty drew coronary arteries on the phantom. The mixture of metal powder (tungsten) and ultraviolet (UV) gel was used to draw the coronary arteries on the heart phantom. In the final stage, the phantom was verified by obtaining and comparing fluoroscopic images of the phantom to reference coronary angiograms from the literature.</p><p><strong>Results: </strong>When comparing the images of the phantom with the images from the literature, we found that the phantom represents an anatomically correct course of the left and right coronary arteries.</p><p><strong>Conclusions: </strong>It can be concluded that the 3D printing technique can be used to develop an anatomically correct heart phantom with coronary arteries that can be used as a teaching tool for radiographers in fluoroscopic visualization of coronary arteries. Consequently, significantly contributing to a faster and safer practise.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"195-203"},"PeriodicalIF":2.3,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13307010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of thyroid cyst sclerotherapy with polidocanol.","authors":"Ziga Mercun, Laura Martinjak, Edvard Pirnat, Simona Gaberscek, Katja Zaletel, Katica Bajuk Studen","doi":"10.2478/raon-2026-0024","DOIUrl":"10.2478/raon-2026-0024","url":null,"abstract":"<p><strong>Background: </strong>Simple cysts are a common form of thyroid nodules. If the cyst is symptomatic, recurs after fine needle aspiration or increases in size, sclerotherapy of the cyst is indicated. Polidocanol can be used as a sclerosing agent, but there are few studies evaluating the efficacy of polidocanol in the sclerotherapy of thyroid cysts.</p><p><strong>Patients and methods: </strong>We conducted a clinical retrospective study in adult patients diagnosed with a simple thyroid cyst with largest diameter greater than 15 mm. Patients were treated with thyroid cyst sclerotherapy with polidocanol (group A, N = 36), ultrasound-guided fine-needle evacuation of the cyst (group B, N = 41) or they received no treatment and were managed only by follow-up (group C, N = 28). Thereafter, the size of the thyroid cyst at least 12 months after the baseline evaluation was recorded.</p><p><strong>Results: </strong>The three groups of patients did not differ significantly in terms of gender, thyrotropin level, thyroid antibody positivity or thyroglobulin level. However, they differed significantly in age (46.5 ± 15.8 years for group A, 51.2 ± 17.4 years for group B and 65.8 ± 13.7 years for group C, p < 0.001). The three patient groups differed significantly in the initial volume of cysts (20.1 ± 13.8 mL for group A, 15.0 ± 17.8 mL for group B and 4.2 ± 4.5 mL for group C, p < 0.001). In groups A and B, the final volume of the cyst was significantly lower than the initial volume (7.6 ± 12.1 mL, p < 0.001, and 6.1 ± 10.4 mL, p < 0.001, respectively), but not in group C (5.3 ± 7.9 mL). There was no significant difference in final cyst volume between the three groups (p = 0.764).</p><p><strong>Conclusions: </strong>The results of our study show that sclerotherapy of thyroid cysts with polidocanol is an effective and safe method for the treatment of large thyroid cysts. Currently, such treatment is more commonly used in younger patients.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"282-287"},"PeriodicalIF":2.3,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13307002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}